Article
Cell Biology
Irina Gromova, Jaime A. Espinoza, Morten Grauslund, Eric Santoni-Rugiu, Maj-Lis Moller Talman, Jan van Oostrum, Jose M. A. Moreira
Summary: Triple-negative breast cancer (TNBC) is a subtype of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, often requiring conventional chemotherapy for treatment. Analysis of protein activation state revealed heterogenous pathway activation, with PI3 K/AKT/mTOR signaling being the most common event. Individualized therapeutic possibilities, such as targeting oncogenic KIT in association with specific protein markers, may have clinical value.
Article
Oncology
Marine Lemesle, Marine Geoffroy, Fabien Alpy, Catherine-Laure Tomasetto, Sandra Kuntz, Isabelle Grillier-Vuissoz
Summary: This study investigated the role of CLDN1 in triple-negative breast cancer (TNBC) and found that CLDN1 can increase the sensitivity of TNBC cells to chemotherapy drugs. The findings support the use of CLDN1 as a predictive marker for chemotherapy response in TNBC.
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Xu Yang, Li Deng, Xianhong Diao, Siyuan Yang, Li Zou, Qin Yang, Jian Li, Jianyun Nie, Lina Zhao, Baowei Jiao
Summary: The compound zinc pyrithione (ZnPT) has been identified as a potent inhibitor of triple-negative breast cancer (TNBC) progression by disrupting copper homeostasis, offering a potential experimental foundation for exploring cuproptosis as a target for drug discovery in TNBC patients.
Article
Biotechnology & Applied Microbiology
Quanyuan Wan, Zihua Zeng, Jianjun Qi, Zhenghu Chen, Xiaohui Liu, Youli Zu
Summary: The study demonstrates the effectiveness of targeted chemotherapy for triple-negative breast cancer using a DNA nanoparticle to deliver doxorubicin to cancer cells, showing promising results in vitro and in animal experiments while potentially reducing side effects for patients.
Article
Oncology
Rui Han, Hongxing Yang, Changquan Ling, Lingeng Lu
Summary: In this study, the therapeutic potential of Tiliroside (TS) in triple negative breast cancer (TNBC) was evaluated. The results showed that TS exhibited anti-cancer activity, reduced tumor burden, and improved survival rate in TNBC. Additionally, TS acted as a CAXII inhibitor to suppress TNBC progression.
CANCER CELL INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Che-Pei Kung, Kyle A. Cottrell, Sua Ryu, Emily R. Bramel, Raleigh D. Kladney, Emily A. Bao, Eric C. Freeman, Thwisha Sabloak, Leonard Maggi Jr., Jason D. Weber
Summary: Triple-negative breast cancer (TNBC) is the deadliest form of breast cancer with no targeted therapy available. The ADAR1 enzyme, highly expressed in TNBC, is essential for the survival of TNBC cell lines. Knockdown of ADAR1 in TNBC cells attenuates proliferation and tumorigenesis, leading to translational repression and elevated IFN stimulated gene expression. These findings establish ADAR1 as a novel therapeutic target for TNBC tumors.
Letter
Medicine, General & Internal
Shuvadeep Ganguly, Ajay Gogia
Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Oncology
Aysha Alneyadi, Zohra Nausheen Nizami, Hanan E. E. Aburawi, Soleiman Hisaindee, Muhammad Nawaz, Samir Attoub, Gaber Ramadan, Nehla Benhalilou, Mazoun Al Azzani, Yassine Elmahi, Aysha Almeqbali, Khalid Muhammad, Ali H. H. Eid, Ranjit Vijayan, Rabah Iratni
Summary: This study synthesized two new chromene compounds and tested their activity against hormone-responsive and TNBC cells. The compounds specifically inhibited the proliferation of TNBC cells and disrupted the polymerization of microtubules within the cytoskeleton. Additionally, the compounds efficiently blocked TNBC migration and inhibited the formation of blood vessels. These findings highlight the therapeutic potential of these compounds against TNBC.
Article
Biochemistry & Molecular Biology
Yuetong Liu, Ge Hong, Lina Mao, Zhe Su, Tianjun Liu, Hong Liu
Summary: PTX-TTHA, a novel semi-synthetic taxane, shows improved water solubility and antitumor activity against triple-negative breast cancer. It inhibits tumor proliferation, induces apoptosis, and has no acute toxicity on vital organs.
Article
Biochemistry & Molecular Biology
Dang Tan Nguyen, Thi Khanh Le, Clement Paris, Chaima Cherif, Stephane Audebert, Sandra Oluchi Udu-Ituma, Sebastien Benizri, Philippe Barthelemy, Francois Bertucci, David Taieb, Palma Rocchi
Summary: The study reveals that in triple-negative breast cancer (TNBC), menin promotes tumorigenesis by regulating transcriptional activity, mRNA 3'-end processing, and apoptosis. Inhibiting menin expression with antisense oligonucleotide (ASO) suppresses cell proliferation and enhances apoptosis in TNBC cells, suggesting a potential therapeutic strategy for menin-positive TNBC.
Review
Pharmacology & Pharmacy
Yifeng Cao, Chuyang Chen, Yi Tao, Weifeng Lin, Ping Wang
Summary: Triple-negative breast cancer (TNBC) is characterized by extensive tumor heterogeneity at both the pathologic and molecular levels, leading to increased mortality of patients due to accelerated aggressiveness and terrible metastasis. Hindered by the negative expression of certain receptors, targeted therapy has been challenging, but the higher immune response in TNBC compared to other breast cancer types makes it suitable for immunotherapy.
Article
Oncology
Alaa Bawaneh, Adam S. Wilson, Nicole Levi, Marissa M. Howard-McNatt, Akiko Chiba, David R. Soto-Pantoja, Katherine L. Cook
Summary: This study demonstrates the impact of neoadjuvant chemotherapy on gut microbiota composition in triple-negative breast cancer (TNBC) and suggests that gut microbiota could be used as a predictive biomarker for doxorubicin responsiveness. Modulating gut microbiota through antibiotics, diet-derived fecal microbiota transplantation, or by exogenous LPS administration can influence tumor growth, treatment response, and metastasis formation.
Review
Biochemistry & Molecular Biology
Halima Alsamri, Yusra Al Dhaheri, Rabah Iratni
Summary: Triple-negative breast cancer (TNBC) lacks the expression of hormone receptors and is highly aggressive and lethal. Conventional therapies and chemotherapeutic agents have limited effectiveness against TNBC. Phytochemicals, such as carnosol, have shown efficacy against TNBC by targeting key pathways involved in cancer development and progression. This review discusses the molecular mechanisms of carnosol in inhibiting TNBC and identifies it as a potential novel targeting protein degradation molecule.
Article
Chemistry, Medicinal
Cheng Wang, Xinye Chen, Xingchen Liu, Dehua Lu, Shang Li, Lailiang Qu, Fucheng Yin, Heng Luo, Yonglei Zhang, Zhongwen Luo, Ningjie Cui, Lingyi Kong, Xiaobing Wang
Summary: EZH2 is often overexpressed in TNBC and other tumors, affecting tumor development and prognosis. The designed PROTACs molecule U3i precision targets EZH2 and shows good inhibitory effects on TNBC cells, inducing apoptosis without causing much damage to normal cells. U3i is a potential anticancer molecule for TNBC treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Letter
Medical Laboratory Technology
Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Annie Ren, Eleftherios P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Letter
Oncology
Georgia Sotiropoulou, Eleni Zingkou, Georgios Pampalakis
CANCER BIOLOGY & THERAPY
(2022)
Editorial Material
Oncology
Amaia Fernandez-Uriarte, Oscar D. Pons-Belda, Eleftherios P. Diamandis
Summary: Cancer screening has been an important field of research. Traditional biomarkers are not suitable for population screening. Circulating tumor DNA has emerged as a promising new marker for cancer, but there are still challenges and the accuracy of new screening tests needs further definition.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Biochemistry & Molecular Biology
Stavroula Kostoudi, Georgios Pampalakis
Summary: Compounds with phosphorus-carbon (P-C) bonds have significant pharmacological, biochemical, and toxicological properties. The Michaelis-Arbuzov reaction, a notable method for forming P-C bonds, has undergone modifications and expansions in its application, resulting in a broader range of reactants and products.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Georgios Angelis, Georgios Sant, Ioannis S. Vizirianakis, Georgios Pampalakis
Summary: Chemobrionic architectures are generated by slowly injecting aqueous silicate solution into gaseous TiCl4. These structures were characterized using XRD, SEM, and wet chemistry control experiments, and their formation mechanism was discovered. They serve as laboratory models for studying the formation of calthemites or soda straws.
CHEMICAL COMMUNICATIONS
(2023)
Letter
Medical Laboratory Technology
Eleftherios. P. P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Medical Laboratory Technology
Ivan Pasic, Annie H. Ren, Ram Vasudevan Nampoothiri, Ioannis Prassas, Jeffrey H. Lipton, Jonas Mattsson, Eleftherios P. Diamandis, Fotios V. Michelis
Summary: Using a novel multiplex antibody-based proximity extension assay, researchers identified serum proteins, including SLAMF7, IL-1ra, BTN3A2, and DAB2, that may potentially serve as biomarkers for acute graft-vs.-host disease.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Medical Laboratory Technology
Annie H. Ren, Panagiota S. Filippou, Antoninus Soosaipillai, Lampros Dimitrakopoulos, Dimitrios Korbakis, Felix Leung, Vathany Kulasingam, Marcus Q. Bernardini, Eleftherios P. Diamandis
Summary: This study explored the potential of using MUC13 as an ovarian cancer biomarker to complement CA125. The results showed that MUC13 could be used to detect non-serous ovarian carcinoma and early-stage disease, in addition to CA125.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Hannu Koistinen, Ruusu-Maaria Kovanen, Morley D. Hollenberg, Antoine Dufour, Evette S. Radisky, Ulf-Hakan Stenman, Jyotsna Batra, Judith Clements, John D. Hooper, Eleftherios Diamandis, Oliver Schilling, Antti Rannikko, Tuomas Mirtti
Summary: Since the proposition of the pro-invasive activity of proteolytic enzymes over 70 years ago, several roles for proteases in cancer progression have been established. About half of the 473 active human proteases are expressed in the prostate and many of the most well-characterized members of this enzyme family are regulated by androgens, hormones essential for development of prostate cancer. Most notably, several kallikrein-related peptidases, including KLK3 (prostate-specific antigen, PSA), the most well-known prostate cancer marker, and type II transmembrane serine proteases, such as TMPRSS2 and matriptase, have been extensively studied and found to promote prostate cancer progression. Recent findings also suggest a critical role for proteases in the development of advanced and aggressive castration-resistant prostate cancer (CRPC). Perhaps the most intriguing evidence for this role comes from studies showing that the protease-activated transmembrane proteins, Notch and CDCP1, are associated with the development of CRPC.
Letter
Medical Laboratory Technology
Eleftherios P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Oncology
Timo-Pekka K. Lehto, Ruusu-Maaria Kovanen, Susanna Lintula, Adrian Malen, Carolin Sturenberg, Andrew Erickson, Olli-Pekka Pulkka, Ulf-Hakan Stenman, Eleftherios P. Diamandis, Antti Rannikko, Tuomas Mirtti, Hannu Koistinen
Summary: This study aimed to investigate the mRNA levels and prognostic impact of all 15 human kallikrein-related peptidases (KLKs) and their targets, proteinase-activated receptors (PARs), in surgically treated prostate cancer (PCa). The results showed that the expression of KLK2, KLK3, KLK4, and KLK15 was closely associated with tumor aggressiveness and prognosis, suggesting their potential as prognostic biomarkers for PCa.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Georgios Pampalakis, Stavroula Kostoudi
Summary: The study provides a comprehensive overview of V-agents, categorizing them based on their structures to facilitate further research. It also describes the production, physical properties, toxicity, and storage stability of V-agents. The high toxicity and stability of V-agents make them a serious percutaneous hazard, with the potential to contaminate exposed areas for weeks.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Medical Laboratory Technology
Eleftherios P. Diamandis
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Letter
Medicine, General & Internal
Sok-Ja Janket, Jukka H. Meurman, Eleftherios P. Diamandis
Review
Medicine, General & Internal
Arsani Yousef, Lucianna Ghobrial, Eleftherios P. Diamandis
Summary: Tumors vary in location, tissue type, and histological subtype. This review highlights current classification schemes for tumor heterogeneity and discusses its clinical significance. New molecular techniques offer affordable assessment of tumor heterogeneity, potentially revolutionizing cancer diagnosis and treatment. Standardized and reproducible assessment methods are needed to fully realize the benefits of tumor heterogeneity.
Article
Oncology
Andra S. Martinikova, Miroslav Stoyanov, Anna Oravetzova, Yannick P. Kok, Shibo Yu, Jana Dobrovolna, Pavel Janscak, Marcel van Vugt, Libor Macurek
Summary: Oncogene-induced replication stress is a major cause of genome instability in cancer cells. This study reveals that increased activity of PPM1D exacerbates replication stress caused by cyclin E1 overexpression, leading to abnormal cell cycle progression and accumulation of DNA copy number alterations. Pharmacological inhibition of PPM1D can alleviate replication stress-induced genome instability.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Alamelu G. Bharadwaj, Meghan E. McLean, Margaret L. Dahn, Hannah F. Cahill, Marie-Claire D. Wasson, Raj Pranap Arun, Olivia L. Walker, Brianne M. Cruickshank, Wasundara Fernando, Jaganathan Venkatesh, Penelope J. Barnes, Gillian Bethune, Gregory Knapp, Lucy K. Helyer, Carman A. Giacomantonio, David M. Waisman, Paola Marcato
Summary: ALDH1A3 regulates the plasminogen activation pathway to promote breast cancer metastasis. Co-expression of ALDH1A3 and tPA is associated with TNBC subtype, high tumor grade, and recurrent metastatic disease.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nayela N. Chowdhury, Yi Yang, Ananya Dutta, Michelle Luo, Zimu Wei, Sara R. Abrahams, Alexey S. Revenko, Fenil Shah, Lindsey A. Miles, Robert J. Parmer, Bas de Laat, Alisa S. Wolberg, James P. Luyendyk, Melissa L. Fishel, Matthew J. Flick
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. Primary fibrinolytic protease plasminogen promotes PDAC tumor growth and metastatic potential through engaging plasminogen receptors on tumor cells.
MOLECULAR ONCOLOGY
(2024)
Article
Oncology
Nuria Gendrau-Sanclemente, Agnes Figueras, Kristina Gracova, Alvaro Lahiguera, Elisenda Alsina-Sanchis, Juan A. Marin-Jimenez, August Vidal, Xavier Matias-Guiu, Sergi Fernandez-Gonzalez, Marc Barahona, Lola Marti, Jordi Ponce, Francesc Vinals
Summary: High-grade serous ovarian cancer (HGSOC), the deadliest gynecological malignancy, spreads through transcoelomic dissemination. This study reveals that platelet-derived growth factor receptor beta (PDGFRβ) is essential for the formation of tumorspheres in HGSOC. Inhibition of PDGFRβ blocks the clustering of ovarian cancer cells and prevents peritoneal dissemination.
MOLECULAR ONCOLOGY
(2024)